Patents
Patents for G01N 33 - Investigating or analysing materials by specific methods not covered by groups (393,632)
12/2003
12/18/2003WO2003046179A3 G-protein coupled receptor lustr2 and uses thereof
12/18/2003WO2003042774A3 Mass intensity profiling system and uses thereof
12/18/2003WO2003042405A3 Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
12/18/2003WO2003041562A3 Molecular cancer diagnosis using tumor gene expression signature
12/18/2003WO2003040726A3 Screening for hepatitis c virus entry inhibitors
12/18/2003WO2003037164A3 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
12/18/2003WO2003036294A3 Articles of manufacture for detecting toxic substances
12/18/2003WO2003033437A3 A method of forming neuraminidase inhibitors by dynamic combinatorial chemistry and compounds obtained
12/18/2003WO2003033096A3 Method and separating module for the separation of particles from a dispersion, in particular of blood corpuscles from blood
12/18/2003WO2003029437A3 Secreted proteins
12/18/2003WO2003025583A3 Differential diagnosis of disorders of iron metabolism
12/18/2003WO2003024304A3 Detection and treatment of cancers of the liver
12/18/2003WO2003023391A3 Method and agents for direct measurement of vitamin d compounds in serum or plasma
12/18/2003WO2003023057A3 Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
12/18/2003WO2003021271A3 Affinity-assay for the human erg potassium channel
12/18/2003WO2003021267A3 Improved mass spectrometric analysis using nanoparticles
12/18/2003WO2003015829A3 Methods of determining the effects of toxins
12/18/2003WO2003014377A3 Competitive binding assay for identifying inhibitors of hcv polymerase
12/18/2003WO2003014342A3 Identification of a dna variant associated with adult type hypolactasia
12/18/2003WO2003008930A3 Lfa-1 binding agents that recognize neoepitopes
12/18/2003WO2003002068A3 Diagnosis and treatment of cancer
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2003000228A3 Method for high through put screening using a small scale mill or microfluidics
12/18/2003WO2002103324A3 Method and device for withdrawing a sample from a fluid batch
12/18/2003WO2002100265A3 Control solution packets and methods for calibrating fluid sampling devices
12/18/2003WO2002099421A3 Specific microarrays for breast cancer screening
12/18/2003WO2002099073A3 Method of assessing levels of infectious virus in a biological sample
12/18/2003WO2002097045A3 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore
12/18/2003WO2002095059A3 Selection of target sites for antisense attack of rna
12/18/2003WO2002093171A3 Method for predicting the risk of transplant rejection and immunological testkit
12/18/2003WO2002093124A3 Markers for evaluating estrogenic activity
12/18/2003WO2002092788A3 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
12/18/2003WO2002089731A3 Agents for treatment of hcv and methods of use
12/18/2003WO2002087417A3 Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity
12/18/2003WO2002082087A3 Diagnosis and treatment of enterococcus faecium related disease
12/18/2003WO2002081627A3 Methods of screening and using inhibitors of angiogenesis
12/18/2003WO2002079486A3 Milieux de detection specific de staphylococcus aureus
12/18/2003WO2002072773A3 Methods and compositions for amplification of rna sequences
12/18/2003WO2002062960A3 Cell fusion assays for the identification of antiviral compounds, and systems and kits for practicing the same
12/18/2003WO2002059623A8 Methods for determining platelet activity with antiplatelet compositions
12/18/2003WO2002059371B1 Genome-wide location and function of dna binding proteins
12/18/2003WO2002059144A3 Differential labeling for quantitative analysis of complex protein mixtures
12/18/2003WO2002057492A9 Methods and compositions for detecting polynucleotide duplex damage
12/18/2003WO2002057423A3 Isolating cells expressing secreted proteins
12/18/2003WO2002054072A3 Assay to determine efficacy of treatment for mycobacterial infection
12/18/2003WO2002053778A3 Method for relative quantification of attached nucleic acids
12/18/2003WO2002040720A8 Compositions and methods relating to ovary specific genes and proteins
12/18/2003WO2002014536A9 Odulating multiple lineage kinase proteins
12/18/2003WO2002007678A3 Mu-conopeptides
12/18/2003US20030233218 Systems and methods for constructing genomic-based phenotypic models
12/18/2003US20030233214 Probabilistic map for a building
12/18/2003US20030233197 Discrete bayesian analysis of data
12/18/2003US20030233196 Method for processing expression data of genes
12/18/2003US20030233035 Methods and devices for diagnosing and treating choroid plexus failure
12/18/2003US20030232979 Nucleic acid labeling compounds
12/18/2003US20030232975 Comprises nucleotide sequences coding polypeptides for diagnosing, preventing and treating cancer
12/18/2003US20030232967 Method for preparation of microarrays for screening of crystal growth conditions
12/18/2003US20030232840 Oxazolidinone photoaffinity probes
12/18/2003US20030232819 Monoamine transporter inhibitors; used for early diagnosis and treatment of neurological and psychiatric conditions
12/18/2003US20030232801 Identification of compounds for the treatment or prevention of proliferative diseases
12/18/2003US20030232792 Useful for male contraception, treatment of a variety of hormone-related conditions such as sexual disorders, prostate cancer
12/18/2003US20030232791 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
12/18/2003US20030232776 Identifying a compound controlling the gene expression, for treating nervous system disorders, with a gene therapy
12/18/2003US20030232762 Therapeutic treating breast cancer
12/18/2003US20030232750 Indolicidin peptide analogues containing at least two basic amino acids; bactericide
12/18/2003US20030232749 Methods for SHP1 mediated neuroprotection
12/18/2003US20030232745 Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
12/18/2003US20030232744 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
12/18/2003US20030232740 A polynucleotide sequence encoding Cathepsin Y or a amino acid sequence of cathepsin Y protein for identification of therapeutic agent for stroke
12/18/2003US20030232738 Increasing JAK3 (Janus kinase) action in CD4+ T lymphocytes of the patient infected with human immunodeficiency virus (HIV), wherein such CD4+ T lymphocytes express CD4 that has been ligated by gp120 on human immunodeficiency virus
12/18/2003US20030232451 Diagnostic test apparatus comprising immunoassay strip for screening and detecting drugs of abuse
12/18/2003US20030232447 Water chloramination control system
12/18/2003US20030232446 Occult blood detection in biological samples by laser desorption and matrix-assisted laser desorption/ionization mass spectrometry for biomedical applications
12/18/2003US20030232444 Assay and method for quantifying the levels of steryl esters and free sterols in starch-containing food products
12/18/2003US20030232421 Protein-protein interactions in adipocyte cells (3)
12/18/2003US20030232409 Genetically engineered swine cell for use as models in cancer treatment and diagnosis
12/18/2003US20030232405 Producing fluorescence from fluorogenic acridine substrates reactive with a peroxidase enzyme; use in assays for peroxidase enzymes
12/18/2003US20030232402 Peptide nucleic acids for detecting bacteria in air, food, beverages, water, pharmaceutical, personal care, dairy, mail and/or packaging product
12/18/2003US20030232401 Measuring the bacteria content of fluids; high throughput assay
12/18/2003US20030232400 Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
12/18/2003US20030232399 Diagnosing tumors via measurement of gastrin, kallikrein, annexin and vasopressin marker proteins
12/18/2003US20030232397 Concurrent measurement of preferential immunoglobulins in blood sample; diagnosing allergies
12/18/2003US20030232396 Method and use of protein microarray technology and proteomic analysis to determine efficacy of human and xenographic cell, tissue and organ transplant
12/18/2003US20030232395 Recombination of nucleic acid library members
12/18/2003US20030232394 High throughput screening method and assay system for determining the interaction between C-reactive protein and components binding to it
12/18/2003US20030232393 Diagnosis and treatment of disorders of iron metabolism
12/18/2003US20030232392 Comprises soluble liver antigen auto-antibodies; fusion proteins
12/18/2003US20030232391 Identification of kinase inhibitors
12/18/2003US20030232390 Which has a shape to be wound on a spindle member, and on the surface of which the material can be immobilized via covalent bonding
12/18/2003US20030232389 NMR structure of the peptidic urokinase type plasminogen activator antagonist has been solved to identify design strategies for peptidomimetics that interfere with the binding of urokinase type plasminogen activator with its receptor
12/18/2003US20030232388 Enhancing particle structures and beads which can have receptor molecules attached thereto; used to detect nucleic acids, proteins, cytokines, hormones, vitamins, those from bacteria, viruses, cells and tissues, and other molecules
12/18/2003US20030232386 Conjugate comprises at least 10 labels, a hydrophilic carrier, a heterobifunctional linker, and an analyte-specific binding pair member such as an antibody or antigen which complexes with the antigen or antibody of interest
12/18/2003US20030232385 Methods of diagnoisis, prognosis and treatment of cardiovascular disease
12/18/2003US20030232383 Synthesized by Escherichia coli (E. coli) in a precursor form in the cytoplasm and exported into the periplasmic space upon cleavage of the 23 amino acid leader sequence
12/18/2003US20030232381 Fiber array and methods for using and making same
12/18/2003US20030232380 Probe array substrate for detecting target substrance
12/18/2003US20030232379 Includes initial contact with a first substrate to produce a substrate supported sample, resultant supported sample is contacted with an array of different ligands, and the presence of any resultant surface bound binding complexes is detected
12/18/2003US20030232377 Based on fetal cells present in peripheral maternal blood; a method for isolating fetal cells from maternal blood
12/18/2003US20030232376 Determining interference or disturbance in the co-modulation mechanism between androgen receptor proteins and the coactivator arginine methyltransferase (HSRNAAM)
12/18/2003US20030232374 Involved in pathogenesis of impaired detrusor contractility; useful in the diagnosis and treatment of DERP- related conditions such as impaired detrusor contractility, urinary retention, Alzheimer's disease, cardiovascular disease and